Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Tesaro raises $40mm in Series B; brings in $60.8mm more

Executive Summary

Tesaro Inc. (supportive cancer therapeutics) has secured $101mm in Series B funding, $40mm of which has already been received through the sale of convertible preferred shares. Kleiner Perkins Caufield & Byers led, joined by founding backer New Enterprise Associates (which committed $40mm of the total amount) and new investors InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Management, Leerink Swann, and nine other buyers. Partners from Kleiner Perkins and InterWest have joined the company's board. Proceeds will help bring Tesaro's lead candidate rolapitant (in-licensed from Opko Health last year) through Phase III trials for chemotherapy-induced nausea and vomiting.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies